ReShape Lifesciences Inc. (RSLS)

ReShape Lifesciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	4.12	0.69	4.46	3.86	22.77	2.96
Cash & Short-Term Investments	4.12	0.69	4.46	3.86	22.77	2.96
Cash Growth	291.55%	-84.46%	15.67%	-83.07%	669.87%	0.75%
Accounts Receivable	0.78	0.99	1.66	2.18	2.82	2.62
Receivables	1.38	0.99	1.66	2.18	2.82	2.62
Inventory	2.55	2.46	3.74	3.61	3	2.24
Prepaid Expenses	0.71	0.33	0.2	0.08	1.12	0.91
Restricted Cash	0.1	0.1	0.1	0.1	0.05	0.05
Other Current Assets	-	0.01	0.14	0.08	0.19	0.16
Total Current Assets	8.86	4.59	10.3	9.91	29.94	8.94
Property, Plant & Equipment	0.11	0.15	0.31	0.87	1.72	1.05
Other Intangible Assets	-	-	-	0.26	20.83	27.02
Long-Term Deferred Tax Assets	0.03	0.02	0.03	0.06	-	-
Other Long-Term Assets	0.03	0.03	0.03	0.05	0.05	0.05
Total Assets	9.03	4.79	10.66	11.14	52.53	37.06

Liabilities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Accounts Payable	1.35	2.21	1.69	1.93	3.47	3.66
Accrued Expenses	1.59	0.89	0.86	2.15	2.13	2.45
Current Portion of Long-Term Debt	-	0.81	-	-	-	3.61
Current Portion of Leases	0.1	0.12	0.11	0.17	0.28	0.31
Current Income Taxes Payable	-	0.03	0.06	0.12	0.33	0.27
Other Current Liabilities	0.16	0.93	1.06	3.12	1.33	1.31
Total Current Liabilities	3.2	4.99	3.78	7.48	7.53	11.61
Long-Term Debt	-	-	-	-	-	9.17
Long-Term Leases	-	0.04	0.15	-	-	0.16
Long-Term Deferred Tax Liabilities	-	-	-	-	0.37	0.62
Other Long-Term Liabilities	-	0.02	0.07	-	0.3	1.02
Total Liabilities	3.2	5.05	4	7.48	8.2	22.57

Shareholders' Equity

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Common Stock	-	-	-	0	-	0
Additional Paid-In Capital	649.8	642.56	642.33	627.94	622.4	529.43
Retained Earnings	-643.86	-642.7	-635.57	-624.19	-577.97	-514.83
Comprehensive Income & Other	-0.11	-0.1	-0.09	-0.09	-0.09	-0.12
Total Common Equity	5.83	-0.25	6.66	3.66	44.33	14.49
Shareholders' Equity	5.83	-0.25	6.66	3.66	44.33	14.49
Total Liabilities & Equity	9.03	4.79	10.66	11.14	52.53	37.06

Additional Metrics

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Total Debt	0.1	0.97	0.26	0.17	0.28	13.25
Net Cash (Debt)	4.02	-0.27	4.2	3.68	22.49	-10.3
Net Cash Growth	380.17%	-	13.93%	-83.62%	-	-
Net Cash Per Share	49.41	-13.29	-	-	-	-
Filing Date Shares Outstanding	0.67	0.45	0.02	-	-	-
Total Common Shares Outstanding	0.66	0.03	0.02	-	-	-
Working Capital	5.66	-0.4	6.52	2.43	22.41	-2.66
Book Value Per Share	8.89	-8.66	411.88	-	-	-
Tangible Book Value	5.83	-0.25	6.66	3.4	23.51	-12.54
Tangible Book Value Per Share	8.89	-8.66	411.88	-	-	-
Machinery	-	0.15	0.15	0.94	1.36	0.34
Construction In Progress	-	-	-	0.07	0.41	0.4
Leasehold Improvements	-	-	-	0.02	0.02	0.02

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Data Sources Report a data error